APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiepileptic Drugs，AEDs

Epilepsy is a chronic brain disease caused by multiple causes and characterized by recurrent, unprovoked seizures. At present, it is mainly believed that epilepsy is characterized by repeated, episodic and transient central nervous system dysfunction caused by excessive discharge of brain neurons. Epilepsy is usually diagnosed when two or more unprovoked epileptic seizures occur. Partial seizures are the most common. Uncontrolled seizures are associated with lifestyle restrictions and social impairment and can lead to serious adverse outcomes, including severe trauma, depression, anxiety, and sudden death. Antiepileptic drugs (AEDs), also known as anticonvulsants, are drugs used to prevent epilepsy (epilepsy) attacks. People with epilepsy need to take one or more AEDs regularly. AEDs interact with nerve cells in the brain, often reducing their activity. Different AEDs work through a variety of mechanisms, so each type of epilepsy responds to some AEDs and not others

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Epilepsy is a chronic brain disease caused by multiple causes and characterized by recurrent, unprovoked seizures. At present, it is mainly believed that epilepsy is characterized by repeated, episodic and transient central nervous system dysfunction caused by excessive discharge of brain neurons. Epilepsy is usually diagnosed when two or more unprovoked epileptic seizures occur. Partial seizures are the most common. Uncontrolled seizures are associated with lifestyle restrictions and social impairment and can lead to serious adverse outcomes, including severe trauma, depression, anxiety, and sudden death. Antiepileptic drugs (AEDs), also known as anticonvulsants, are drugs used to prevent epilepsy (epilepsy) attacks. People with epilepsy need to take one or more AEDs regularly. AEDs interact with nerve cells in the brain, often reducing their activity. Different AEDs work through a variety of mechanisms, so each type of epilepsy responds to some AEDs and not others

Selected research

Market Structure

Global Antiepileptic Drugs，AEDs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025194 pages

Choose your research edition.

Industry ResearchAntiepileptic Drugs，AEDs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiepileptic Drugs，AEDs Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Antiepileptic Drugs，AEDs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiepileptic Drugs，AEDs Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiepileptic Drugs，AEDs Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

Epilepsy is a chronic brain disease caused by multiple causes and characterized by recurrent, unprovoked seizures. At present, it is mainly believed that epilepsy is characterized by repeated, episodic and transient central nervous system dysfunction caused by excessive discharge of brain neurons. Epilepsy is usually diagnosed when two or more unprovoked epileptic seizures occur. Partial seizures are the most common. Uncontrolled seizures are associated with lifestyle restrictions and social impairment and can lead to serious adverse outcomes, including severe trauma, depression, anxiety, and sudden death. Antiepileptic drugs (AEDs), also known as anticonvulsants, are drugs used to prevent epilepsy (epilepsy) attacks. People with epilepsy need to take one or more AEDs regularly. AEDs interact with nerve cells in the brain, often reducing their activity. Different AEDs work through a variety of mechanisms, so each type of epilepsy responds to some AEDs and not others

The global Antiepileptic Drugs，AEDs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antiepileptic Drugs，AEDs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Europe market for Antiepileptic Drugs，AEDs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Antiepileptic Drugs，AEDs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antiepileptic Drugs，AEDs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antiepileptic Drugs，AEDs include Novartis, Pfizer, GlaxoSmithKline, Eisai, Roche, Shanghai Pharmaceuticals Holding, Gilead Sciences, UCB and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antiepileptic Drugs，AEDs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiepileptic Drugs，AEDs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiepileptic Drugs，AEDs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antiepileptic Drugs，AEDs market size, projected growth trends, production technologies, key applications, and end-use industries.

Antiepileptic Drugs，AEDs Segment by Company

Novartis

Pfizer

GlaxoSmithKline

Eisai

Roche

Shanghai Pharmaceuticals Holding

Gilead Sciences

UCB

Johnson & Johnson

Lupin Pharmaceuticals

Mylan N.V.

Sanofi

Teva Pharmaceutical Industries

Abbott

Sunovion

Shenzhen Salubris Pharmaceuticals

Chongqing Shenghuaxi Pharm

Zhejiang Jingxin Pharmaceutical

Zhuhai United Laboratories

Hubei Jumpcan Pharmaceutical

Zhejiang Huahai Pharmaceutical

China Resources SAIKE Pharmaceutical

Sihuan Pharmaceutical Holdings

Apeloa Pharmaceutical

Sandoz

Aurobindo Pharma

Yangtze River Pharmaceutical

Antiepileptic Drugs，AEDs Segment by Type

First Generation AEDs

Second Generation AEDs

Third Generation AEDs

Antiepileptic Drugs，AEDs Segment by Application

≤15 Years Old

15～40 Years Old

>40～65 Years Old

>65 Years Old

Antiepileptic Drugs，AEDs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiepileptic Drugs，AEDs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiepileptic Drugs，AEDs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiepileptic Drugs，AEDs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antiepileptic Drugs，AEDs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antiepileptic Drugs，AEDs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antiepileptic Drugs，AEDs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antiepileptic Drugs，AEDs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antiepileptic Drugs，AEDs Industry Trends Table 2. Antiepileptic Drugs，AEDs Industry Drivers Table 3. Antiepileptic Drugs，AEDs Industry Opportunities and Challenges Table 4. Antiepileptic Drugs，AEDs Industry Restraints Table 5. Global Antiepileptic Drugs，AEDs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antiepileptic Drugs，AEDs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antiepileptic Drugs，AEDs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antiepileptic Drugs，AEDs Sales Market Share by Manufacturers Table 9. Global Antiepileptic Drugs，AEDs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antiepileptic Drugs，AEDs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antiepileptic Drugs，AEDs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antiepileptic Drugs，AEDs Manufacturers, Product Type & Application Table 13. Global Antiepileptic Drugs，AEDs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antiepileptic Drugs，AEDs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of First Generation AEDs Table 17. Major Manufacturers of Second Generation AEDs Table 18. Major Manufacturers of Third Generation AEDs Table 19. Global Antiepileptic Drugs，AEDs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antiepileptic Drugs，AEDs Sales by Type (2021-2026) & (K Units) Table 21. Global Antiepileptic Drugs，AEDs Sales by Type (2027-2032) & (K Units) Table 22. Global Antiepileptic Drugs，AEDs Sales Market Share by Type (2021-2026) Table 23. Global Antiepileptic Drugs，AEDs Sales Market Share by Type (2027-2032) Table 24. Global Antiepileptic Drugs，AEDs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Antiepileptic Drugs，AEDs Revenue by Type (2021-2026) & (K Units) Table 26. Global Antiepileptic Drugs，AEDs Revenue by Type (2027-2032) & (K Units) Table 27. Global Antiepileptic Drugs，AEDs Revenue Market Share by Type (2021-2026) Table 28. Global Antiepileptic Drugs，AEDs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of ≤15 Years Old Table 30. Major Manufacturers of 15～40 Years Old Table 31. Major Manufacturers of >40～65 Years Old Table 32. Major Manufacturers of >65 Years Old Table 33. Global Antiepileptic Drugs，AEDs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Antiepileptic Drugs，AEDs Sales by Application (2021-2026) & (K Units) Table 35. Global Antiepileptic Drugs，AEDs Sales by Application (2027-2032) & (K Units) Table 36. Global Antiepileptic Drugs，AEDs Sales Market Share by Application (2021-2026) Table 37. Global Antiepileptic Drugs，AEDs Sales Market Share by Application (2027-2032) Table 38. Global Antiepileptic Drugs，AEDs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Antiepileptic Drugs，AEDs Revenue by Application (2021-2026) & (K Units) Table 40. Global Antiepileptic Drugs，AEDs Revenue by Application (2027-2032) & (K Units) Table 41. Global Antiepileptic Drugs，AEDs Revenue Market Share by Application (2021-2026) Table 42. Global Antiepileptic Drugs，AEDs Revenue Market Share by Application (2027-2032) Table 43. Global Antiepileptic Drugs，AEDs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Antiepileptic Drugs，AEDs Sales by Region (2021-2026) & (K Units) Table 45. Global Antiepileptic Drugs，AEDs Sales Market Share by Region (2021-2026) Table 46. Global Antiepileptic Drugs，AEDs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Antiepileptic Drugs，AEDs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Antiepileptic Drugs，AEDs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Antiepileptic Drugs，AEDs Sales by Country (2021-2026) & (K Units) Table 50. North America Antiepileptic Drugs，AEDs Sales by Country (2027-2032) & (K Units) Table 51. Europe Antiepileptic Drugs，AEDs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Antiepileptic Drugs，AEDs Sales by Country (2021-2026) & (K Units) Table 53. Europe Antiepileptic Drugs，AEDs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Antiepileptic Drugs，AEDs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Antiepileptic Drugs，AEDs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Antiepileptic Drugs，AEDs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Antiepileptic Drugs，AEDs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Antiepileptic Drugs，AEDs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Antiepileptic Drugs，AEDs Sales by Country (2027-2032) & (K Units) Table 60. Global Antiepileptic Drugs，AEDs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Antiepileptic Drugs，AEDs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Antiepileptic Drugs，AEDs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Antiepileptic Drugs，AEDs Revenue Market Share by Region (2021-2026) Table 64. Global Antiepileptic Drugs，AEDs Revenue Market Share by Region (2027-2032) Table 65. Novartis Company Information Table 66. Novartis Business Overview Table 67. Novartis Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Novartis Antiepileptic Drugs，AEDs Product Portfolio Table 69. Novartis Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pfizer Antiepileptic Drugs，AEDs Product Portfolio Table 74. Pfizer Recent Development Table 75. GlaxoSmithKline Company Information Table 76. GlaxoSmithKline Business Overview Table 77. GlaxoSmithKline Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. GlaxoSmithKline Antiepileptic Drugs，AEDs Product Portfolio Table 79. GlaxoSmithKline Recent Development Table 80. Eisai Company Information Table 81. Eisai Business Overview Table 82. Eisai Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Eisai Antiepileptic Drugs，AEDs Product Portfolio Table 84. Eisai Recent Development Table 85. Roche Company Information Table 86. Roche Business Overview Table 87. Roche Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Roche Antiepileptic Drugs，AEDs Product Portfolio Table 89. Roche Recent Development Table 90. Shanghai Pharmaceuticals Holding Company Information Table 91. Shanghai Pharmaceuticals Holding Business Overview Table 92. Shanghai Pharmaceuticals Holding Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Shanghai Pharmaceuticals Holding Antiepileptic Drugs，AEDs Product Portfolio Table 94. Shanghai Pharmaceuticals Holding Recent Development Table 95. Gilead Sciences Company Information Table 96. Gilead Sciences Business Overview Table 97. Gilead Sciences Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Gilead Sciences Antiepileptic Drugs，AEDs Product Portfolio Table 99. Gilead Sciences Recent Development Table 100. UCB Company Information Table 101. UCB Business Overview Table 102. UCB Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. UCB Antiepileptic Drugs，AEDs Product Portfolio Table 104. UCB Recent Development Table 105. Johnson & Johnson Company Information Table 106. Johnson & Johnson Business Overview Table 107. Johnson & Johnson Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Johnson & Johnson Antiepileptic Drugs，AEDs Product Portfolio Table 109. Johnson & Johnson Recent Development Table 110. Lupin Pharmaceuticals Company Information Table 111. Lupin Pharmaceuticals Business Overview Table 112. Lupin Pharmaceuticals Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Lupin Pharmaceuticals Antiepileptic Drugs，AEDs Product Portfolio Table 114. Lupin Pharmaceuticals Recent Development Table 115. Mylan N.V. Company Information Table 116. Mylan N.V. Business Overview Table 117. Mylan N.V. Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Mylan N.V. Antiepileptic Drugs，AEDs Product Portfolio Table 119. Mylan N.V. Recent Development Table 120. Sanofi Company Information Table 121. Sanofi Business Overview Table 122. Sanofi Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Sanofi Antiepileptic Drugs，AEDs Product Portfolio Table 124. Sanofi Recent Development Table 125. Teva Pharmaceutical Industries Company Information Table 126. Teva Pharmaceutical Industries Business Overview Table 127. Teva Pharmaceutical Industries Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Teva Pharmaceutical Industries Antiepileptic Drugs，AEDs Product Portfolio Table 129. Teva Pharmaceutical Industries Recent Development Table 130. Abbott Company Information Table 131. Abbott Business Overview Table 132. Abbott Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Abbott Antiepileptic Drugs，AEDs Product Portfolio Table 134. Abbott Recent Development Table 135. Sunovion Company Information Table 136. Sunovion Business Overview Table 137. Sunovion Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Sunovion Antiepileptic Drugs，AEDs Product Portfolio Table 139. Sunovion Recent Development Table 140. Shenzhen Salubris Pharmaceuticals Company Information Table 141. Shenzhen Salubris Pharmaceuticals Business Overview Table 142. Shenzhen Salubris Pharmaceuticals Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Shenzhen Salubris Pharmaceuticals Antiepileptic Drugs，AEDs Product Portfolio Table 144. Shenzhen Salubris Pharmaceuticals Recent Development Table 145. Chongqing Shenghuaxi Pharm Company Information Table 146. Chongqing Shenghuaxi Pharm Business Overview Table 147. Chongqing Shenghuaxi Pharm Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Chongqing Shenghuaxi Pharm Antiepileptic Drugs，AEDs Product Portfolio Table 149. Chongqing Shenghuaxi Pharm Recent Development Table 150. Zhejiang Jingxin Pharmaceutical Company Information Table 151. Zhejiang Jingxin Pharmaceutical Business Overview Table 152. Zhejiang Jingxin Pharmaceutical Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Zhejiang Jingxin Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio Table 154. Zhejiang Jingxin Pharmaceutical Recent Development Table 155. Zhuhai United Laboratories Company Information Table 156. Zhuhai United Laboratories Business Overview Table 157. Zhuhai United Laboratories Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Zhuhai United Laboratories Antiepileptic Drugs，AEDs Product Portfolio Table 159. Zhuhai United Laboratories Recent Development Table 160. Hubei Jumpcan Pharmaceutical Company Information Table 161. Hubei Jumpcan Pharmaceutical Business Overview Table 162. Hubei Jumpcan Pharmaceutical Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Hubei Jumpcan Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio Table 164. Hubei Jumpcan Pharmaceutical Recent Development Table 165. Zhejiang Huahai Pharmaceutical Company Information Table 166. Zhejiang Huahai Pharmaceutical Business Overview Table 167. Zhejiang Huahai Pharmaceutical Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Zhejiang Huahai Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio Table 169. Zhejiang Huahai Pharmaceutical Recent Development Table 170. China Resources SAIKE Pharmaceutical Company Information Table 171. China Resources SAIKE Pharmaceutical Business Overview Table 172. China Resources SAIKE Pharmaceutical Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. China Resources SAIKE Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio Table 174. China Resources SAIKE Pharmaceutical Recent Development Table 175. Sihuan Pharmaceutical Holdings Company Information Table 176. Sihuan Pharmaceutical Holdings Business Overview Table 177. Sihuan Pharmaceutical Holdings Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 178. Sihuan Pharmaceutical Holdings Antiepileptic Drugs，AEDs Product Portfolio Table 179. Sihuan Pharmaceutical Holdings Recent Development Table 180. Apeloa Pharmaceutical Company Information Table 181. Apeloa Pharmaceutical Business Overview Table 182. Apeloa Pharmaceutical Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 183. Apeloa Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio Table 184. Apeloa Pharmaceutical Recent Development Table 185. Sandoz Company Information Table 186. Sandoz Business Overview Table 187. Sandoz Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 188. Sandoz Antiepileptic Drugs，AEDs Product Portfolio Table 189. Sandoz Recent Development Table 190. Aurobindo Pharma Company Information Table 191. Aurobindo Pharma Business Overview Table 192. Aurobindo Pharma Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 193. Aurobindo Pharma Antiepileptic Drugs，AEDs Product Portfolio Table 194. Aurobindo Pharma Recent Development Table 195. Yangtze River Pharmaceutical Company Information Table 196. Yangtze River Pharmaceutical Business Overview Table 197. Yangtze River Pharmaceutical Antiepileptic Drugs，AEDs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 198. Yangtze River Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio Table 199. Yangtze River Pharmaceutical Recent Development Table 200. Key Raw Materials Table 201. Raw Materials Key Suppliers Table 202. Antiepileptic Drugs，AEDs Distributors List Table 203. Antiepileptic Drugs，AEDs Customers List Table 204. Research Programs/Design for This Report Table 205. Authors List of This Report Table 206. Secondary Sources Table 207. Primary Sources List of Figures Figure 1. Antiepileptic Drugs，AEDs Product Image Figure 2. Global Antiepileptic Drugs，AEDs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiepileptic Drugs，AEDs Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiepileptic Drugs，AEDs Sales (2021-2032) & (K Units) Figure 5. Global Antiepileptic Drugs，AEDs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antiepileptic Drugs，AEDs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. First Generation AEDs Image Figure 9. Second Generation AEDs Image Figure 10. Third Generation AEDs Image Figure 11. Global Antiepileptic Drugs，AEDs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Antiepileptic Drugs，AEDs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Antiepileptic Drugs，AEDs Sales Market Share by Type (2021-2032) Figure 14. Global Antiepileptic Drugs，AEDs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Antiepileptic Drugs，AEDs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Antiepileptic Drugs，AEDs Revenue Market Share by Type (2021-2032) Figure 17. ≤15 Years Old Image Figure 18. 15～40 Years Old Image Figure 19. >40～65 Years Old Image Figure 20. >65 Years Old Image Figure 21. Global Antiepileptic Drugs，AEDs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Antiepileptic Drugs，AEDs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Antiepileptic Drugs，AEDs Sales Market Share by Application (2021-2032) Figure 24. Global Antiepileptic Drugs，AEDs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Antiepileptic Drugs，AEDs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Antiepileptic Drugs，AEDs Revenue Market Share by Application (2021-2032) Figure 27. North America Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Antiepileptic Drugs，AEDs Sales Market Share by Country (2021-2032) Figure 29. U.S. Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Antiepileptic Drugs，AEDs Sales Market Share by Country (2021-2032) Figure 34. Germany Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Antiepileptic Drugs，AEDs Sales Market Share by Country (2021-2032) Figure 41. China Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Antiepileptic Drugs，AEDs Sales Market Share by Country (2021-2032) Figure 49. Brazil Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Antiepileptic Drugs，AEDs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Antiepileptic Drugs，AEDs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Antiepileptic Drugs，AEDs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Antiepileptic Drugs，AEDs Revenue (2021-2032) & (US$ Million) Figure 60. North America Antiepileptic Drugs，AEDs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Antiepileptic Drugs，AEDs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Antiepileptic Drugs，AEDs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Antiepileptic Drugs，AEDs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Antiepileptic Drugs，AEDs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Antiepileptic Drugs，AEDs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Antiepileptic Drugs，AEDs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Antiepileptic Drugs，AEDs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Antiepileptic Drugs，AEDs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • First Generation AEDs
  • Second Generation AEDs
  • Third Generation AEDs
Applications
  • ≤15 Years Old
  • 15～40 Years Old
  • >40～65 Years Old
  • >65 Years Old
Companies covered
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • Eisai
  • Roche
  • Shanghai Pharmaceuticals Holding
  • Gilead Sciences
  • UCB
  • Johnson & Johnson
  • Lupin Pharmaceuticals
  • Mylan N.V.
  • Sanofi
  • Teva Pharmaceutical Industries
  • Abbott
  • Sunovion
  • Shenzhen Salubris Pharmaceuticals
  • Chongqing Shenghuaxi Pharm
  • Zhejiang Jingxin Pharmaceutical
  • Zhuhai United Laboratories
  • Hubei Jumpcan Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • China Resources SAIKE Pharmaceutical
  • Sihuan Pharmaceutical Holdings
  • Apeloa Pharmaceutical
  • Sandoz
  • Aurobindo Pharma
  • Yangtze River Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antiepileptic Drugs，AEDs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antiepileptic Drugs，AEDs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antiepileptic Drugs，AEDs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antiepileptic Drugs，AEDs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antiepileptic Drugs，AEDs Market Dynamics
  1. 2.1 Antiepileptic Drugs，AEDs Industry Trends
  2. 2.2 Antiepileptic Drugs，AEDs Industry Drivers
  3. 2.3 Antiepileptic Drugs，AEDs Industry Opportunities and Challenges
  4. 2.4 Antiepileptic Drugs，AEDs Industry Restraints
3 Antiepileptic Drugs，AEDs Market by Manufacturers
  1. 3.1 Global Antiepileptic Drugs，AEDs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antiepileptic Drugs，AEDs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antiepileptic Drugs，AEDs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antiepileptic Drugs，AEDs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antiepileptic Drugs，AEDs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antiepileptic Drugs，AEDs Manufacturers, Product Type & Application
  7. 3.7 Global Antiepileptic Drugs，AEDs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antiepileptic Drugs，AEDs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antiepileptic Drugs，AEDs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antiepileptic Drugs，AEDs Tier 1, Tier 2, and Tier 3
4 Antiepileptic Drugs，AEDs Market by Type
  1. 4.1 Antiepileptic Drugs，AEDs Type Introduction
  2. 4.1.1 First Generation AEDs
  3. 4.1.2 Second Generation AEDs
  4. 4.1.3 Third Generation AEDs
  5. 4.2 Global Antiepileptic Drugs，AEDs Sales by Type
  6. 4.2.1 Global Antiepileptic Drugs，AEDs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antiepileptic Drugs，AEDs Sales by Type (2021-2032)
  8. 4.2.3 Global Antiepileptic Drugs，AEDs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Antiepileptic Drugs，AEDs Revenue by Type
  10. 4.3.1 Global Antiepileptic Drugs，AEDs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Antiepileptic Drugs，AEDs Revenue by Type (2021-2032)
  12. 4.3.3 Global Antiepileptic Drugs，AEDs Revenue Market Share by Type (2021-2032)
5 Antiepileptic Drugs，AEDs Market by Application
  1. 5.1 Antiepileptic Drugs，AEDs Application Introduction
  2. 5.1.1 ≤15 Years Old
  3. 5.1.2 15～40 Years Old
  4. 5.1.3 >40～65 Years Old
  5. 5.1.4 >65 Years Old
  6. 5.2 Global Antiepileptic Drugs，AEDs Sales by Application
  7. 5.2.1 Global Antiepileptic Drugs，AEDs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antiepileptic Drugs，AEDs Sales by Application (2021-2032)
  9. 5.2.3 Global Antiepileptic Drugs，AEDs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Antiepileptic Drugs，AEDs Revenue by Application
  11. 5.3.1 Global Antiepileptic Drugs，AEDs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Antiepileptic Drugs，AEDs Revenue by Application (2021-2032)
  13. 5.3.3 Global Antiepileptic Drugs，AEDs Revenue Market Share by Application (2021-2032)
6 Global Antiepileptic Drugs，AEDs Sales by Region
  1. 6.1 Global Antiepileptic Drugs，AEDs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiepileptic Drugs，AEDs Sales by Region (2021-2032)
  3. 6.2.1 Global Antiepileptic Drugs，AEDs Sales by Region (2021-2026)
  4. 6.2.2 Global Antiepileptic Drugs，AEDs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antiepileptic Drugs，AEDs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antiepileptic Drugs，AEDs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antiepileptic Drugs，AEDs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antiepileptic Drugs，AEDs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antiepileptic Drugs，AEDs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antiepileptic Drugs，AEDs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antiepileptic Drugs，AEDs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antiepileptic Drugs，AEDs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antiepileptic Drugs，AEDs Revenue by Region
  1. 7.1 Global Antiepileptic Drugs，AEDs Revenue by Region
  2. 7.1.1 Global Antiepileptic Drugs，AEDs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antiepileptic Drugs，AEDs Revenue by Region (2021-2026)
  4. 7.1.3 Global Antiepileptic Drugs，AEDs Revenue by Region (2027-2032)
  5. 7.1.4 Global Antiepileptic Drugs，AEDs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antiepileptic Drugs，AEDs Revenue (2021-2032)
  8. 7.2.2 North America Antiepileptic Drugs，AEDs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antiepileptic Drugs，AEDs Revenue (2021-2032)
  11. 7.3.2 Europe Antiepileptic Drugs，AEDs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antiepileptic Drugs，AEDs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antiepileptic Drugs，AEDs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antiepileptic Drugs，AEDs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antiepileptic Drugs，AEDs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Antiepileptic Drugs，AEDs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Antiepileptic Drugs，AEDs Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Antiepileptic Drugs，AEDs Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Eisai
  20. 8.4.1 Eisai Company Information
  21. 8.4.2 Eisai Business Overview
  22. 8.4.3 Eisai Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eisai Antiepileptic Drugs，AEDs Product Portfolio
  24. 8.4.5 Eisai Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Antiepileptic Drugs，AEDs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Shanghai Pharmaceuticals Holding
  32. 8.6.1 Shanghai Pharmaceuticals Holding Company Information
  33. 8.6.2 Shanghai Pharmaceuticals Holding Business Overview
  34. 8.6.3 Shanghai Pharmaceuticals Holding Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Pharmaceuticals Holding Antiepileptic Drugs，AEDs Product Portfolio
  36. 8.6.5 Shanghai Pharmaceuticals Holding Recent Developments
  37. 8.7 Gilead Sciences
  38. 8.7.1 Gilead Sciences Company Information
  39. 8.7.2 Gilead Sciences Business Overview
  40. 8.7.3 Gilead Sciences Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gilead Sciences Antiepileptic Drugs，AEDs Product Portfolio
  42. 8.7.5 Gilead Sciences Recent Developments
  43. 8.8 UCB
  44. 8.8.1 UCB Company Information
  45. 8.8.2 UCB Business Overview
  46. 8.8.3 UCB Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 UCB Antiepileptic Drugs，AEDs Product Portfolio
  48. 8.8.5 UCB Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson Antiepileptic Drugs，AEDs Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
  55. 8.10 Lupin Pharmaceuticals
  56. 8.10.1 Lupin Pharmaceuticals Company Information
  57. 8.10.2 Lupin Pharmaceuticals Business Overview
  58. 8.10.3 Lupin Pharmaceuticals Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lupin Pharmaceuticals Antiepileptic Drugs，AEDs Product Portfolio
  60. 8.10.5 Lupin Pharmaceuticals Recent Developments
  61. 8.11 Mylan N.V.
  62. 8.11.1 Mylan N.V. Company Information
  63. 8.11.2 Mylan N.V. Business Overview
  64. 8.11.3 Mylan N.V. Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Mylan N.V. Antiepileptic Drugs，AEDs Product Portfolio
  66. 8.11.5 Mylan N.V. Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Antiepileptic Drugs，AEDs Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Teva Pharmaceutical Industries
  74. 8.13.1 Teva Pharmaceutical Industries Company Information
  75. 8.13.2 Teva Pharmaceutical Industries Business Overview
  76. 8.13.3 Teva Pharmaceutical Industries Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Teva Pharmaceutical Industries Antiepileptic Drugs，AEDs Product Portfolio
  78. 8.13.5 Teva Pharmaceutical Industries Recent Developments
  79. 8.14 Abbott
  80. 8.14.1 Abbott Company Information
  81. 8.14.2 Abbott Business Overview
  82. 8.14.3 Abbott Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Abbott Antiepileptic Drugs，AEDs Product Portfolio
  84. 8.14.5 Abbott Recent Developments
  85. 8.15 Sunovion
  86. 8.15.1 Sunovion Company Information
  87. 8.15.2 Sunovion Business Overview
  88. 8.15.3 Sunovion Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sunovion Antiepileptic Drugs，AEDs Product Portfolio
  90. 8.15.5 Sunovion Recent Developments
  91. 8.16 Shenzhen Salubris Pharmaceuticals
  92. 8.16.1 Shenzhen Salubris Pharmaceuticals Company Information
  93. 8.16.2 Shenzhen Salubris Pharmaceuticals Business Overview
  94. 8.16.3 Shenzhen Salubris Pharmaceuticals Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Shenzhen Salubris Pharmaceuticals Antiepileptic Drugs，AEDs Product Portfolio
  96. 8.16.5 Shenzhen Salubris Pharmaceuticals Recent Developments
  97. 8.17 Chongqing Shenghuaxi Pharm
  98. 8.17.1 Chongqing Shenghuaxi Pharm Company Information
  99. 8.17.2 Chongqing Shenghuaxi Pharm Business Overview
  100. 8.17.3 Chongqing Shenghuaxi Pharm Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Chongqing Shenghuaxi Pharm Antiepileptic Drugs，AEDs Product Portfolio
  102. 8.17.5 Chongqing Shenghuaxi Pharm Recent Developments
  103. 8.18 Zhejiang Jingxin Pharmaceutical
  104. 8.18.1 Zhejiang Jingxin Pharmaceutical Company Information
  105. 8.18.2 Zhejiang Jingxin Pharmaceutical Business Overview
  106. 8.18.3 Zhejiang Jingxin Pharmaceutical Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Zhejiang Jingxin Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio
  108. 8.18.5 Zhejiang Jingxin Pharmaceutical Recent Developments
  109. 8.19 Zhuhai United Laboratories
  110. 8.19.1 Zhuhai United Laboratories Company Information
  111. 8.19.2 Zhuhai United Laboratories Business Overview
  112. 8.19.3 Zhuhai United Laboratories Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Zhuhai United Laboratories Antiepileptic Drugs，AEDs Product Portfolio
  114. 8.19.5 Zhuhai United Laboratories Recent Developments
  115. 8.20 Hubei Jumpcan Pharmaceutical
  116. 8.20.1 Hubei Jumpcan Pharmaceutical Company Information
  117. 8.20.2 Hubei Jumpcan Pharmaceutical Business Overview
  118. 8.20.3 Hubei Jumpcan Pharmaceutical Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Hubei Jumpcan Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio
  120. 8.20.5 Hubei Jumpcan Pharmaceutical Recent Developments
  121. 8.21 Zhejiang Huahai Pharmaceutical
  122. 8.21.1 Zhejiang Huahai Pharmaceutical Company Information
  123. 8.21.2 Zhejiang Huahai Pharmaceutical Business Overview
  124. 8.21.3 Zhejiang Huahai Pharmaceutical Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Zhejiang Huahai Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio
  126. 8.21.5 Zhejiang Huahai Pharmaceutical Recent Developments
  127. 8.22 China Resources SAIKE Pharmaceutical
  128. 8.22.1 China Resources SAIKE Pharmaceutical Company Information
  129. 8.22.2 China Resources SAIKE Pharmaceutical Business Overview
  130. 8.22.3 China Resources SAIKE Pharmaceutical Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 China Resources SAIKE Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio
  132. 8.22.5 China Resources SAIKE Pharmaceutical Recent Developments
  133. 8.23 Sihuan Pharmaceutical Holdings
  134. 8.23.1 Sihuan Pharmaceutical Holdings Company Information
  135. 8.23.2 Sihuan Pharmaceutical Holdings Business Overview
  136. 8.23.3 Sihuan Pharmaceutical Holdings Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Sihuan Pharmaceutical Holdings Antiepileptic Drugs，AEDs Product Portfolio
  138. 8.23.5 Sihuan Pharmaceutical Holdings Recent Developments
  139. 8.24 Apeloa Pharmaceutical
  140. 8.24.1 Apeloa Pharmaceutical Company Information
  141. 8.24.2 Apeloa Pharmaceutical Business Overview
  142. 8.24.3 Apeloa Pharmaceutical Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Apeloa Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio
  144. 8.24.5 Apeloa Pharmaceutical Recent Developments
  145. 8.25 Sandoz
  146. 8.25.1 Sandoz Company Information
  147. 8.25.2 Sandoz Business Overview
  148. 8.25.3 Sandoz Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Sandoz Antiepileptic Drugs，AEDs Product Portfolio
  150. 8.25.5 Sandoz Recent Developments
  151. 8.26 Aurobindo Pharma
  152. 8.26.1 Aurobindo Pharma Company Information
  153. 8.26.2 Aurobindo Pharma Business Overview
  154. 8.26.3 Aurobindo Pharma Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Aurobindo Pharma Antiepileptic Drugs，AEDs Product Portfolio
  156. 8.26.5 Aurobindo Pharma Recent Developments
  157. 8.27 Yangtze River Pharmaceutical
  158. 8.27.1 Yangtze River Pharmaceutical Company Information
  159. 8.27.2 Yangtze River Pharmaceutical Business Overview
  160. 8.27.3 Yangtze River Pharmaceutical Antiepileptic Drugs，AEDs Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Yangtze River Pharmaceutical Antiepileptic Drugs，AEDs Product Portfolio
  162. 8.27.5 Yangtze River Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antiepileptic Drugs，AEDs Value Chain Analysis
  2. 9.1.1 Antiepileptic Drugs，AEDs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antiepileptic Drugs，AEDs Production Mode & Process
  6. 9.2 Antiepileptic Drugs，AEDs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antiepileptic Drugs，AEDs Distributors
  9. 9.2.3 Antiepileptic Drugs，AEDs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst